MOLECULAR RESPONSE
Molecular Response provides clinical support services range from trial-site sample collection to clinical analysis for drug development.
MOLECULAR RESPONSE
Industry:
Biotechnology Clinical Trials Health Care
Founded:
2010-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.molecularresponse.com
Total Employee:
1+
Status:
Closed
Contact:
8586222938
Technology used in webpage:
IPhone / Mobile Compatible SPF LetsEncrypt IPv6 Google Maps Cloudflare Hosting Cloudflare DNS Sectigo SSL Sectigo Domain SSL Unified Layer
Similar Organizations
Carolina BioOnocology Institute
Carolina BioOnocology Institute provides clinical, nursing, research and clinical trials assistance along with cancer treatment services.
UCT (U.S.), Inc
UCT (U.S.), Inc provides central laboratory services for clinical trials to the pharmaceutical and biotechnology industries.
Current Advisors List
Official Site Inspections
http://www.molecularresponse.com Semrush global rank: 3.75 M Semrush visits lastest month: 1.18 K
- Host name: 104.21.32.1
- IP address: 104.21.32.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Molecular Response"
Molecular Response - Crunchbase Company Profile & Funding
Molecular Response provides clinical support services range from trial-site sample collection to clinical analysis for drug development. Where is Molecular Response's headquarters? …See details»
Molecular Response - Crunchbase Company Profile & Funding
Molecular Response is an oncology research platform that comprises the largest collection of viable tumor specimens.See details»
BioDuro Acquires Molecular Response Cancer Biobank …
Mar 5, 2018 · BioDuro LLC is a global life sciences contract research and development organization (CRO). The company has acquired Molecular Response LLC and its extensive cancer biobank of >100,000 viable tumors, …See details»
BioDuro Acquires Molecular Response - bridgewestgroup.com
BioDuro acquires Molecular Response and its world-class translational oncology research platform, including its biobank of >100,000 viable tumor specimens.See details»
Molecular Response Company Profile 2024: Valuation, Investors ...
The company's advanced human biologic platforms provide a clinically relevant molecular response and biomarker data that accelerate novel or improved therapeutic drug development …See details»
Molecular Response - Scientist.com
Molecular Response is an oncology-focused CRO, with a viable primary tumor bank of more than 140,000 clinical biopsies, spanning 76 diagnoses. Tumors are employed to create Patient …See details»
Molecular Response LLC: Drug pipelines, Patents, Clinical trials
Jul 8, 2023 · Explore Molecular Response LLC with its drug pipeline, therapeutic area, technology platform, .See details»
Novartis Scemblix® shows superior major molecular response …
Basel, January 08, 2024 — Novartis today announced positive results from the primary analysis of ASC4FIRST, a pivotal Phase III trial comparing Scemblix ® (asciminib) with investigators’ …See details»
Standardization of molecular monitoring of CML: results and ...
May 25, 2022 · Molecular monitoring of chronic myeloid leukemia (CML) patients undergoing tyrosine kinase inhibitor (TKI) therapy provides important prognostic information for individual …See details»
Improving outcomes in chronic myeloid leukemia through …
Apr 8, 2021 · The quest for treatment-free remission (TFR) and deep molecular response (DMR) in chronic myeloid leukemia (CML) has been profoundly impacted by tyrosine kinase inhibitors …See details»
Analyzing molecular response in chronic myeloid …
Oct 24, 2014 · Surrogate markers and correlates in chronic myeloid leukemia (CML) are shown, using the example of molecular response and survival using targeted therapy against BCR-ABL1. Case 1 was a surrogate. In this case, …See details»
Molecular monitoring in chronic myeloid leukemia—how low can …
Molecular monitoring of BCR-ABL1 transcripts for patients with chronic myeloid leukemia (CML) is now used to assess response to tyrosine kinase inhibitors (TKIs), including treatment failure …See details»
Major Molecular Response in Chronic Myeloid Leukemia (CML)
Mar 8, 2023 · Molecular response is one of the ways that doctors monitor the effectiveness of your CML treatment. It’s a measure of how many cells in your blood and bone marrow carry …See details»
Major Molecular Response in CML Patients Treated with Tyrosine …
Jun 21, 2010 · RQ-PCR testing defines “molecular response” and can be done with a simple blood draw, making it safer and more convenient than bone marrow testing. The depth of a …See details»
Successful maintenance of a sustained molecular response in CML ...
Jun 14, 2024 · Lowering the TKI dose can effectively preserve a deep molecular response over time while relieving adverse events caused by TKIs. The introduction of tyrosine kinase …See details»
Standardized definitions of molecular response in chronic myeloid ...
Apr 16, 2012 · Most patients with chronic-phase chronic myeloid leukemia (CML-CP) on imatinib therapy achieve a complete cytogenetic response (CCyR) that is maintained for long term.See details»
Chronic Myeloid Leukemia (CML) | Treatment Response | LLS
For patients with CML, adhering to treatment is associated with the probability of achieving and improving long-term outcomes, including achieving a major molecular response and improved …See details»
Molecular response in CML: where is the bar?
Jul 24, 2014 · For almost 10 years, the main goal of the treatment of CML with tyrosine kinase inhibitors (TKIs) has been the achievement of the so-called “major molecular response” (MMR; …See details»
Molecular response in newly diagnosed chronic-phase chronic …
Tyrosine kinase inhibitor therapy revolutionized chronic myeloid leukemia treatment and showed how targeted therapy and molecular monitoring could be used to substantially improve survival …See details»
Defining therapy goals for major molecular remission in chronic …
Feb 26, 2018 · Major molecular remission (MMR) is an important therapy goal in chronic myeloid leukemia (CML). So far, MMR is not a failure criterion according to ELN management …See details»